Navigation Links
MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome

SAN DIEGO, Jan. 14, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase II clinical trial of Pracinostat, the Company's investigational oral histone deacetylase (HDAC) inhibitor, in patients with myelodysplastic syndrome (MDS) who either failed to respond or maintain a response to a hypomethylating agent (HMA) alone.


"We are very excited about getting this study underway," said Robert D. Mass, MD, Chief Medical Officer of MEI Pharma. "This represents the third in a series of Phase II clinical trials we are conducting with Pracinostat in combination with HMAs in an attempt to establish the clinical benefit of selectively combining two epigenetic modifiers. The primary objective in this refractory MDS trial is to determine if the addition of Pracinostat to Vidaza® or Dacogen® can improve clinical responses or rescue previous responses achieved with a HMA alone. We look forward to reporting preliminary data from all three Phase II trials of Pracinostat later this year."

This two-stage trial of Pracinostat is expected to enroll up to a total of 76 patients into two groups: 1) patients who have had disease progression or have relapsed following a clinical response to either Vidaza or Dacogen therapy and 2) patients with stable disease who failed to respond to their initial HMA therapy. If at any time two or more responses are observed in the first 29 patients of each group, that group will continue to enroll an additional nine patients in the second stage, for a total of up to 38 evaluable patients per group. Preliminary data from this open-label trial is anticipated by December 2014.

The primary endpoint of the trial is clinical improvement rate, defined as the proportion of patients with complete remission (CR), partial remission (PR) and hematologic improvement (HI). Secondary endpoints include overall response rate, CR rate, HI rate, duration of response, progression-free survival, time to progression and overall survival. Dr. Guillermo Garcia-Manero of the MD Anderson Cancer Center is the study's Principal Investigator. Additional information regarding the trial is available at

Meanwhile, MEI Pharma remains on track to fully enroll its randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza in patients with previously untreated intermediate-2 or high-risk MDS by June 2014, with topline data expected by December 2014.

In addition, the Company continues to enroll patients in a two-stage Phase II trial of Pracinostat in combination with Vidaza in elderly patients with newly diagnosed acute myeloid leukemia (AML). If at any time three or more responses are observed in the first 27 patients, the trial will continue to enroll an additional 13 patients in the second stage, for a total of up to 40 evaluable patients. Preliminary data from this open-label trial is also anticipated by December 2014.

About Pracinostat

Pracinostat is an orally available HDAC inhibitor that has been tested in a number of Phase I and Phase II clinical trials in advanced hematologic disorders and solid tumor indications. Pracinostat has been generally well tolerated in more than 200 adult and pediatric patients to date, with readily manageable side effects that are often associated with drugs of this class, including fatigue. In a Phase I dose-escalation trial, Pracinostat demonstrated evidence of single-agent activity in elderly AML patients, including two out of 14 (14%) who achieved a CR, with durable responses persisting 206+ and 362 days, respectively. In addition, results from a pilot Phase II study of Pracinostat in combination with Vidaza in patients with advanced MDS showed an overall response rate of 90% (nine out of 10), including eight patients who achieved either a CR or a CR with incomplete blood count recovery (CRi).

MEI Pharma owns exclusive worldwide rights to Pracinostat.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor being developed for advanced hematologic diseases, including MDS and AML. Results from a pilot Phase II clinical trial of Pracinostat in combination with Vidaza in patients with advanced MDS showed an overall response rate of 90% (nine out of 10). MEI Pharma is also developing ME-344, a mitochondrial inhibitor that has showed preliminary evidence of single-agent activity in a first-in-human clinical study in patients with refractory solid tumors. In September 2013, the Company further expanded its pipeline of drug candidates with the acquisition of PWT143, a highly selective PI3-kinase delta inhibitor. For more information, go to

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 As enforcement of the ... Security Act (DSCSA) approaches, InfiniTrak announced ... pharmacies comply with looming FDA regulations. ... entering endorsement agreements with State Pharmacy Associations, an ... organization (PSAO) to exclusively provide the InfiniTrak track-and-trace ...
(Date:12/1/2015)... CLEVELAND , Dec. 1, 2015   ... innovation firm, today announced the publication of a ... Entering the Direct-to-Consumer Medical Market". The whitepaper gives ... roadmap for successfully penetrating this lucrative segment. ... purchase healthcare products to manage their own health, ...
(Date:12/1/2015)... 2015 --> --> ... Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, ... Pipeline Analysis - Global Forecast to 2020", published by MarketsandMarkets, ... 73,529.2 Million by 2020 from USD 40,281.6 Million in 2015, ... Browse 37 market data T ...
Breaking Medicine Technology:
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... keeping their independence is everything. That is why Hollister Incorporated has launched the ... to offer this next product in the VaPro touch free catheter portfolio,” said ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... that it has been selected as a finalist in this year’s Fierce Innovation ... FierceMobileHealthcare. Next IT Healthcare was recognized as a finalist in the category of ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), a ... health arenas, is pleased to announce that VIP Care Services, a Caprock Health ... the ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ...
(Date:12/1/2015)... ... 2015 , ... PartnerTech , a leader in high-tech ... 2008. Gary Bruce, President of PartnerTech North America, currently serves as Director for ... of time in Sweden since joining PartnerTech based in Malmo, Sweden. He has ...
(Date:12/1/2015)... ... 01, 2015 , ... Dr. Arash Moradzadeh of was ... , Angeleno Magazine is a division of Modern Luxury, which is the ... includes more than 50 magazine titles across 15 major markets. The magazine reaches ...
Breaking Medicine News(10 mins):